NRX Pharmaceuticals Files 8-K on Financials

TL;DR

NRXP filed an 8-K detailing financial condition and results of operations as of Nov 14, 2024.

AI Summary

NRX Pharmaceuticals, Inc. filed an 8-K on November 15, 2024, reporting on its financial condition and results of operations as of November 14, 2024. The filing also includes Regulation FD disclosures and financial statements. The company was formerly known as Big Rock Partners Acquisition Corp. and changed its name on October 12, 2017.

Why It Matters

This filing provides investors with crucial updates on NRX Pharmaceuticals' financial health and operational performance, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not appear to contain significant new risks.

Key Players & Entities

• NRX Pharmaceuticals, Inc. (company) — Registrant
• Big Rock Partners Acquisition Corp. (company) — Former company name
• November 14, 2024 (date) — Date of earliest event reported
• November 15, 2024 (date) — Filing date
• October 12, 2017 (date) — Date of name change

FAQ

Key Financial Figures

• $0.001 — registered Common Stock, par value $0.001 pershare NRXP The Nasdaq Stock Mark

Filing Documents

• nrxp20241115_8k.htm (8-K) — 33KB
• ex_748946.htm (EX-99.1) — 46KB
• graph01.jpg (GRAPHIC) — 38KB
• graph02.jpg (GRAPHIC) — 18KB
• graph03.jpg (GRAPHIC) — 34KB
• nrx01.jpg (GRAPHIC) — 2KB
• 0001437749-24-035521.txt ( ) — 365KB
• nrxp-20241114.xsd (EX-101.SCH) — 4KB
• nrxp-20241114_def.xml (EX-101.DEF) — 13KB
• nrxp-20241114_lab.xml (EX-101.LAB) — 17KB
• nrxp-20241114_pre.xml (EX-101.PRE) — 13KB
• nrxp20241115_8k_htm.xml (XML) — 5KB

02

Item 2.02 Results of Operations and Financial Condition On November 14, 2024, NRx Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the third quarter ending September 30, 2024, and providing a business update, including an update regarding HOPE Therapeutics, the Company's wholly owned subsidiary (" HOPE ") (the " Press Release ). HOPE intends to develop a national network of precision psychiatry clinics that combine treatment with ketamine, Transcranial Magnetic Stimulation, and other therapies to patients with suicidal depression and PTSD. In furtherance of this objective, the Company disclosed that it has executed two letters of intent (" LOIs ") to acquire foundational Interventional Psychiatric Clinics, which LOIs are non-binding. Consummation of the transactions contemplated by the LOIs are conditioned upon the receipt of adequate financing and the execution of definitive agreements. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

01

Item 7.01 Regulation FD Disclosure. See Item 2.02 above.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 14, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL). The information contained in Items 2.02 and 7.01 of this Current Report on Form 8-K, and Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed " filed " for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act " ), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: November 15, 2024 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR